SlideShare a Scribd company logo
1 of 21
Dissolution Profiles
Dissolution Profiles
Agenda
• Types of Drug Release
• Drug Release Profiling
• Alcohol-Induced Dose Dumping
• Dissolution Release Specification
Types of Drug Release
Types of Drug Release
Delayed Release Orally Disintegrating
In-vitro
disintegrating time
of NMT 30 seconds
Releases a discrete portion or
portions of drug at a time other
than promptly after
administration.
Drug Release Profiling
• Places to check first
• USP
• FDA Dissolution Method
Database
http://www.accessdata.fda.gov/scripts
/cder/dissolution/
• Summary Basis of
Approval
• FDA Bioequivalence
Recommendations for
Specific Products
Drug Name
Dosage
Form
USP
Apparatus
Speed
(RPMs)
Medium Volume (mL)
Recommend
ed Sampling
Times
(minutes)
Date
Updated
Abacavir
Sulfate
Tablet II (Paddle) 75 0.1 N HCl 900 5, 10, 15,
and 30
03/22/2006
Abacavir
Sulfate/Lami
vudine
Tablet II (Paddle) 75 0.1 N HCl 900 10, 20, 30,
and 45
01/03/2007
Abacavir
Sulfate/Lami
vudine/Zidov
udine
Tablet II (Paddle) 75 0.1 N HCl 900 5, 10, 15, 30
and 45
01/03/2007
In addition to the method above, for modified release
products, dissolution profiles on 12 dosage units each
of test and reference products generated using USP
Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in
at least three dissolution media (pH 1.2, 4.5, and 6.8
buffer) should be submitted in the application. Agitation
speeds may have to be increased if appropriate. It is
acceptable to add a small amount of surfactant, if
necessary. Include early sampling times of 1, 2, and 4
hours and continue every 2 hours until at least 80% of
the drug is released, to provide assurance against
premature release of drug (dose dumping) from the
formulation. Specifications will be determined upon
review of the data submitted in the application.
Drug Release Profiling (IR)
Drug Release Profiling (IR)
• Things to do first (Immediate Release)
• 0.1 N HCl, 900 mL, paddles, 50 RPM, 15 min.
If NLT 85% is dissolved, then product behaves like a
solution.
• Using release method, sample dissolution every 15
minutes until two points past the asymptote is
obtained.
For dissolution profiles, select NMT 4 time points with
NMT 2 points past the asymptote. Asymptote should
be NLT 85% amount released.
Drug Release Profiling (ER)
Drug Release Profiling (ER)
• Things to do first
• Generate RLD profile as per FDA Dissolution Data Base.
• Using same apparatus, volume, speed and time points as
FDA method, generate additional profiles* with
• Water
• 0.1N HCl
• Buffer pH 6.8
• Buffer pH 4.5
All together, there should be 4 dissolution profiles: FDA’s
plus three.
*Surfactants may be used to achieve sink conditions
Drug Release Profiling (DR)
• Demonstrate product is
stable at pH 1.2 for 2 hrs.
• Demonstrate drug is
released at pH 6.8.
• No multimedia dissolution
testing required.
Alcohol-Induced Dose Dumping
• Not required for all products.
• Verify FDA’s guidance – Individual Products
Bioequivalence Recommendations Guidance
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm
• Check if it was requested by FDA on RLD SBoA.
• Media: 900 mL 0.1N HCl media on a V/V basis to
give the following percentages:
• 0% ethanol (no ethanol added)
• 5% ethanol (beer)
• 20% ethanol (mixed drinks)
• 40% ethanol (neat liquor)
Beware!
Ethanol ≠ Alcohol
Alcohol is about 94.5% Ethanol…
Alcohol-Induced Dose Dumping
• Sampling is done
every 15 minutes until
2 hrs are reached.
• Acceptance criteria:
Generic drug is not
worst than the RLD.
• It is only performed
once in the lifetime of
a drug product
formula. Prior to
approval.
Data
• No decimal points
• Assays
• RLD should be 95 – 105% LC
• Test product should be within
5% of RLD
• RLD satisfactory Content
Uniformity
• The following may indicate
the need to investigate
results out of the lab
• RSD should be NMT 20% in
first time point.
• RSD should be NMT 10% for
all other points.
• Asymptote should be NLT
85%.
• F2 calculations
• Only one measurement
should be considered after
85% dissolution of the
product.
• Data needs to be
generated and handled as
per cGMP.
Data
Reporting
Data
Reporting
Dissolution Release Specification
• For sampling time points, go to:
• USP
• Summary Basis of Approval
Dissolution Release Specification
Analytical method to be followed should be the
same as that provided by FDA Individual
Dissolution Guideline.
Release time points would be selected from
dissolution profile time points.
Dissolution Release Specification
• IR
• One point with release
of NLT 85%
• DR
• Two points
• 0% @ 2 hr in 0.1N HCl
• Either
• 85% in 6.8 buffer
• Multipoint Dissolution
• ER
• NMT 4 time points
• NMT 2 points past
asymptote
• Asymptote NLT 85%
• Ranges:
• 1st is NMT __%
• 2nd and 3rd with a range of
NMT 20%
• 4th time point NLT 85%
Questions

More Related Content

What's hot

Guidance requirement for evaluation of similarity factor (f2) across global r...
Guidance requirement for evaluation of similarity factor (f2) across global r...Guidance requirement for evaluation of similarity factor (f2) across global r...
Guidance requirement for evaluation of similarity factor (f2) across global r...Jubiliant Generics Limited
 
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSQ1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSBhaumik Bavishi
 
Stabilty study ppt
Stabilty study pptStabilty study ppt
Stabilty study pptpharmacy
 
Basic Approach to Dissolution Method Development – Challenges and Regulatory ...
Basic Approach to Dissolution Method Development – Challenges and Regulatory ...Basic Approach to Dissolution Method Development – Challenges and Regulatory ...
Basic Approach to Dissolution Method Development – Challenges and Regulatory ...Dr. Harshal Pawar
 
selection of dissolution medium And dissolution study of solid dosage form
selection of dissolution medium And dissolution study of solid dosage formselection of dissolution medium And dissolution study of solid dosage form
selection of dissolution medium And dissolution study of solid dosage formAshwin Patil
 
Stability testing protocols
Stability testing protocolsStability testing protocols
Stability testing protocolsMehulJain143
 
Process valiadtion
Process valiadtionProcess valiadtion
Process valiadtionSagar Savale
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptxanumalagundam sreekanth
 
Ich guideline for stability testing
Ich guideline for stability testingIch guideline for stability testing
Ich guideline for stability testingShubham Gore
 
Regulatory requirements-BA/BE Studies
 Regulatory requirements-BA/BE Studies Regulatory requirements-BA/BE Studies
Regulatory requirements-BA/BE StudiesKireeti Bheemavarapu
 
ICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra MohanICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra MohanChandra Mohan
 
Cleaning validation
Cleaning validationCleaning validation
Cleaning validationVinay Jain
 
Dissolution profile comparison
Dissolution profile comparisonDissolution profile comparison
Dissolution profile comparisonMohammad Imran
 
Accelerated stability studies & Expiry Date Calculation of drug substance
Accelerated stability studies & Expiry Date Calculation of drug substanceAccelerated stability studies & Expiry Date Calculation of drug substance
Accelerated stability studies & Expiry Date Calculation of drug substanceharish pandey
 
Stability testing and shelf life estimation
Stability testing and shelf life estimationStability testing and shelf life estimation
Stability testing and shelf life estimationManish sharma
 

What's hot (20)

Guidance requirement for evaluation of similarity factor (f2) across global r...
Guidance requirement for evaluation of similarity factor (f2) across global r...Guidance requirement for evaluation of similarity factor (f2) across global r...
Guidance requirement for evaluation of similarity factor (f2) across global r...
 
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTSQ1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
Q1A(R2): STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
 
Stabilty study ppt
Stabilty study pptStabilty study ppt
Stabilty study ppt
 
Basic Approach to Dissolution Method Development – Challenges and Regulatory ...
Basic Approach to Dissolution Method Development – Challenges and Regulatory ...Basic Approach to Dissolution Method Development – Challenges and Regulatory ...
Basic Approach to Dissolution Method Development – Challenges and Regulatory ...
 
selection of dissolution medium And dissolution study of solid dosage form
selection of dissolution medium And dissolution study of solid dosage formselection of dissolution medium And dissolution study of solid dosage form
selection of dissolution medium And dissolution study of solid dosage form
 
Out of specifications
Out of specificationsOut of specifications
Out of specifications
 
Stability testing protocols
Stability testing protocolsStability testing protocols
Stability testing protocols
 
Process valiadtion
Process valiadtionProcess valiadtion
Process valiadtion
 
Analytical method validation
Analytical method validationAnalytical method validation
Analytical method validation
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptx
 
New guidance on Bioequivalence
New guidance on BioequivalenceNew guidance on Bioequivalence
New guidance on Bioequivalence
 
Ich guideline for stability testing
Ich guideline for stability testingIch guideline for stability testing
Ich guideline for stability testing
 
Regulatory requirements-BA/BE Studies
 Regulatory requirements-BA/BE Studies Regulatory requirements-BA/BE Studies
Regulatory requirements-BA/BE Studies
 
Quality by Design
Quality by DesignQuality by Design
Quality by Design
 
ICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra MohanICH Q6A Specifications by Chandra Mohan
ICH Q6A Specifications by Chandra Mohan
 
Cleaning validation
Cleaning validationCleaning validation
Cleaning validation
 
Preformulation Guide
Preformulation GuidePreformulation Guide
Preformulation Guide
 
Dissolution profile comparison
Dissolution profile comparisonDissolution profile comparison
Dissolution profile comparison
 
Accelerated stability studies & Expiry Date Calculation of drug substance
Accelerated stability studies & Expiry Date Calculation of drug substanceAccelerated stability studies & Expiry Date Calculation of drug substance
Accelerated stability studies & Expiry Date Calculation of drug substance
 
Stability testing and shelf life estimation
Stability testing and shelf life estimationStability testing and shelf life estimation
Stability testing and shelf life estimation
 

Similar to Dissolution Profiles

Developing specifications q3 q6
Developing specifications  q3 q6Developing specifications  q3 q6
Developing specifications q3 q6NamrataBawaskar
 
Dissolution ready ppt
Dissolution ready pptDissolution ready ppt
Dissolution ready pptYasir Mehmood
 
GUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTINGGUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTINGSagar Savale
 
Dissolution procedure development and validation, USP 1092
Dissolution procedure development and validation, USP 1092Dissolution procedure development and validation, USP 1092
Dissolution procedure development and validation, USP 1092Md. Saddam Nawaz
 
Dissolution testing conventional and controlled release products
Dissolution testing  conventional and controlled release productsDissolution testing  conventional and controlled release products
Dissolution testing conventional and controlled release productsMd Fiaz
 
LC-HRMS Method FDA NITROSAMINES REVIEWS A
LC-HRMS Method FDA NITROSAMINES REVIEWS ALC-HRMS Method FDA NITROSAMINES REVIEWS A
LC-HRMS Method FDA NITROSAMINES REVIEWS AAngelGarcia686517
 
Dissolution Technique in pharmaceutical industry
Dissolution Technique in pharmaceutical industryDissolution Technique in pharmaceutical industry
Dissolution Technique in pharmaceutical industryAnil Sharma
 
Dissolution Testing in Pharmaceuticals
Dissolution Testing in PharmaceuticalsDissolution Testing in Pharmaceuticals
Dissolution Testing in PharmaceuticalsPharmaguideline
 
ICH Q3C GUIDELINE
ICH Q3C GUIDELINEICH Q3C GUIDELINE
ICH Q3C GUIDELINEKalyani722
 
CHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.ppt
CHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.pptCHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.ppt
CHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.pptLogesh Kannan
 
1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...
1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...
1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...Soils FAO-GSP
 
Dissolution presentation by subhakanta Dhal
Dissolution presentation by subhakanta DhalDissolution presentation by subhakanta Dhal
Dissolution presentation by subhakanta DhalSubhakanta Dhal
 
Validation of Analytical Process.pptx
Validation of Analytical Process.pptxValidation of Analytical Process.pptx
Validation of Analytical Process.pptxFatenHamed6
 
FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...
FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...
FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...Greenlight Guru
 

Similar to Dissolution Profiles (20)

Developing specifications q3 q6
Developing specifications  q3 q6Developing specifications  q3 q6
Developing specifications q3 q6
 
Dissolution ready ppt
Dissolution ready pptDissolution ready ppt
Dissolution ready ppt
 
GUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTINGGUIDELINES FOR DISSOLUTION TESTING
GUIDELINES FOR DISSOLUTION TESTING
 
Dissolution procedure development and validation, USP 1092
Dissolution procedure development and validation, USP 1092Dissolution procedure development and validation, USP 1092
Dissolution procedure development and validation, USP 1092
 
Love ppt
Love pptLove ppt
Love ppt
 
Dissolution testing conventional and controlled release products
Dissolution testing  conventional and controlled release productsDissolution testing  conventional and controlled release products
Dissolution testing conventional and controlled release products
 
LC-HRMS Method FDA NITROSAMINES REVIEWS A
LC-HRMS Method FDA NITROSAMINES REVIEWS ALC-HRMS Method FDA NITROSAMINES REVIEWS A
LC-HRMS Method FDA NITROSAMINES REVIEWS A
 
Dissolution Technique in pharmaceutical industry
Dissolution Technique in pharmaceutical industryDissolution Technique in pharmaceutical industry
Dissolution Technique in pharmaceutical industry
 
Dissolution Testing in Pharmaceuticals
Dissolution Testing in PharmaceuticalsDissolution Testing in Pharmaceuticals
Dissolution Testing in Pharmaceuticals
 
Dissolution
DissolutionDissolution
Dissolution
 
ICH Q3C GUIDELINE
ICH Q3C GUIDELINEICH Q3C GUIDELINE
ICH Q3C GUIDELINE
 
How to maintain ro
How to maintain roHow to maintain ro
How to maintain ro
 
CHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.ppt
CHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.pptCHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.ppt
CHROMATOGRAPHY vnd.ms-powerpoint&rendition=1-6.ppt
 
1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...
1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...
1st NENALAB Meeting_Item 32: Perform QA/QC in the lab by Rob De Hayr, GLOSOLA...
 
ICH Q6A & ICH Q7
ICH Q6A & ICH Q7ICH Q6A & ICH Q7
ICH Q6A & ICH Q7
 
Workplace Drug Testing: On-Site Screening Versus Laboratory Testing
Workplace Drug Testing: On-Site Screening Versus Laboratory TestingWorkplace Drug Testing: On-Site Screening Versus Laboratory Testing
Workplace Drug Testing: On-Site Screening Versus Laboratory Testing
 
Dissolution presentation by subhakanta Dhal
Dissolution presentation by subhakanta DhalDissolution presentation by subhakanta Dhal
Dissolution presentation by subhakanta Dhal
 
Validation of Analytical Process.pptx
Validation of Analytical Process.pptxValidation of Analytical Process.pptx
Validation of Analytical Process.pptx
 
Chromatography: Pesticide Residue Analysis Webinar Series Pt 1 - Sample Prep ...
Chromatography: Pesticide Residue Analysis Webinar Series Pt 1 - Sample Prep ...Chromatography: Pesticide Residue Analysis Webinar Series Pt 1 - Sample Prep ...
Chromatography: Pesticide Residue Analysis Webinar Series Pt 1 - Sample Prep ...
 
FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...
FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...
FDA Feedback Regarding Chemistry for Toxicological Risk Assessment – How to M...
 

Dissolution Profiles

  • 2. Dissolution Profiles Agenda • Types of Drug Release • Drug Release Profiling • Alcohol-Induced Dose Dumping • Dissolution Release Specification
  • 3. Types of Drug Release
  • 4. Types of Drug Release Delayed Release Orally Disintegrating In-vitro disintegrating time of NMT 30 seconds Releases a discrete portion or portions of drug at a time other than promptly after administration.
  • 5. Drug Release Profiling • Places to check first • USP • FDA Dissolution Method Database http://www.accessdata.fda.gov/scripts /cder/dissolution/ • Summary Basis of Approval • FDA Bioequivalence Recommendations for Specific Products Drug Name Dosage Form USP Apparatus Speed (RPMs) Medium Volume (mL) Recommend ed Sampling Times (minutes) Date Updated Abacavir Sulfate Tablet II (Paddle) 75 0.1 N HCl 900 5, 10, 15, and 30 03/22/2006 Abacavir Sulfate/Lami vudine Tablet II (Paddle) 75 0.1 N HCl 900 10, 20, 30, and 45 01/03/2007 Abacavir Sulfate/Lami vudine/Zidov udine Tablet II (Paddle) 75 0.1 N HCl 900 5, 10, 15, 30 and 45 01/03/2007 In addition to the method above, for modified release products, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5, and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.
  • 7. Drug Release Profiling (IR) • Things to do first (Immediate Release) • 0.1 N HCl, 900 mL, paddles, 50 RPM, 15 min. If NLT 85% is dissolved, then product behaves like a solution. • Using release method, sample dissolution every 15 minutes until two points past the asymptote is obtained. For dissolution profiles, select NMT 4 time points with NMT 2 points past the asymptote. Asymptote should be NLT 85% amount released.
  • 9. Drug Release Profiling (ER) • Things to do first • Generate RLD profile as per FDA Dissolution Data Base. • Using same apparatus, volume, speed and time points as FDA method, generate additional profiles* with • Water • 0.1N HCl • Buffer pH 6.8 • Buffer pH 4.5 All together, there should be 4 dissolution profiles: FDA’s plus three. *Surfactants may be used to achieve sink conditions
  • 10. Drug Release Profiling (DR) • Demonstrate product is stable at pH 1.2 for 2 hrs. • Demonstrate drug is released at pH 6.8. • No multimedia dissolution testing required.
  • 11. Alcohol-Induced Dose Dumping • Not required for all products. • Verify FDA’s guidance – Individual Products Bioequivalence Recommendations Guidance http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm • Check if it was requested by FDA on RLD SBoA. • Media: 900 mL 0.1N HCl media on a V/V basis to give the following percentages: • 0% ethanol (no ethanol added) • 5% ethanol (beer) • 20% ethanol (mixed drinks) • 40% ethanol (neat liquor)
  • 13. Alcohol is about 94.5% Ethanol…
  • 14. Alcohol-Induced Dose Dumping • Sampling is done every 15 minutes until 2 hrs are reached. • Acceptance criteria: Generic drug is not worst than the RLD. • It is only performed once in the lifetime of a drug product formula. Prior to approval.
  • 15. Data • No decimal points • Assays • RLD should be 95 – 105% LC • Test product should be within 5% of RLD • RLD satisfactory Content Uniformity • The following may indicate the need to investigate results out of the lab • RSD should be NMT 20% in first time point. • RSD should be NMT 10% for all other points. • Asymptote should be NLT 85%. • F2 calculations • Only one measurement should be considered after 85% dissolution of the product. • Data needs to be generated and handled as per cGMP.
  • 18. Dissolution Release Specification • For sampling time points, go to: • USP • Summary Basis of Approval
  • 19. Dissolution Release Specification Analytical method to be followed should be the same as that provided by FDA Individual Dissolution Guideline. Release time points would be selected from dissolution profile time points.
  • 20. Dissolution Release Specification • IR • One point with release of NLT 85% • DR • Two points • 0% @ 2 hr in 0.1N HCl • Either • 85% in 6.8 buffer • Multipoint Dissolution • ER • NMT 4 time points • NMT 2 points past asymptote • Asymptote NLT 85% • Ranges: • 1st is NMT __% • 2nd and 3rd with a range of NMT 20% • 4th time point NLT 85%